David Mack, Ph.D.
Director
David joined Alta in 2002, and focuses on investments in biopharmaceutical products and therapeutics. He currently serves on the Board of Directors of Aerie Pharmaceuticals, aTyr Pharma, Ceregene, Intradigm, Proacta Therapeutics, Silence Therapeutics and Sutro Biopharma.
Prior to Alta, David co-founded and served as Vice President of Genomics Research at Eos Biotechnology (acquired by Protein Design Labs in 2003). From 1995 to 1997, he served at Affymetrix as Head of Cancer Biology where he oversaw the development and application of DNA array technology in the areas of oncology and inflammation. David was also a pivotal member of the Polymerase Chain Reaction (PCR) invention group at Cetus (now Chiron) in the mid 1980s.
David has co-authored more than 30 scientific articles and reviews, including papers published in Cell, Science, and Nature, and is an inventor on 24 US patents.
He was an American Cancer Society postdoctoral fellow at Stanford University School of Medicine in Microbiology and Immunology. David received his Ph.D. in 1992 from the University of Chicago where he was a Howard Hughes fellow in Molecular Genetics and Cell Biology. David holds a Bachelor of Arts in Molecular Biology from the University of California, Berkeley.
